Anatomically, this could indicate that the effect of both VIP and PACAP occurs is via the VPAC1 receptor in the basal arteries, but the timeline for induction of migraine after VIP and PACAP infusion is quite different, suggesting separate receptors and downstream pathways. The gene discussed is ADCYAP1; the disease is migraine disorder.